

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**{CARDBOARD BOX}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Milprazon CHEWABLE 12.5 mg/125 mg film-coated tablets

*For memory stickers:*  
*milbemycin oxime/praziquantel*

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each film-coated tablet contains 12.5 mg milbemycin oxime and 125.0 mg praziquantel.

**3. PACKAGE SIZE**

2 tablets  
4 tablets  
48 tablets

**4. TARGET SPECIES**

Dogs (weighing at least 5 kg)



**5. INDICATIONS**

Flavoured broad spectrum anthelmintic

*For products not subject to veterinary prescription:*

Treatment of mixed infections by adult tapeworms and roundworms

**6. ROUTES OF ADMINISTRATION**

Oral use.

*For products not subject to veterinary prescription:*

Dosage:

<b>Body weight</b>	<b>Tablets</b>
5 – 25 kg	1 tablet
>25 – 50 kg	2 tablets
>50 – 75 kg	3 tablets

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from moisture.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

KRKA

**14. MARKETING AUTHORISATION NUMBERS**

Vm 01656/3083

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

{BLISTER}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Milprazon CHEWABLE



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

12.5 mg/125 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Milprazon CHEWABLE 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg

Milprazon CHEWABLE 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg

### 2. Composition

Each film-coated tablet contains:

	Film-coated tablets for small dogs and puppies	Film-coated tablets for dogs
<b>Active substances:</b>		
Milbemycin oxime	2.5 mg	12.5 mg
Praziquantel	25 mg	125 mg

Tablets for small dogs and puppies: Pale yellowish brown, oval, biconvex, mottled, film coated tablets, scored on one side.  
The tablets can be divided into equal halves.

Tablets for dogs: Pale yellowish brown, oval, biconvex, mottled, film coated tablets.

### 3. Target species

Small dogs and puppies (weighing at least 0.5 kg).  
Dogs (weighing at least 5 kg).



### 4. Indications for use

Treatment of mixed infections by adult tapeworms and roundworms of the following species:

- Tapeworms:  
*Dipylidium caninum*  
*Taenia* spp.  
*Echinococcus* spp.  
*Mesocestoides* spp.

- Roundworms:

*Ancylostoma caninum*

*Toxocara canis*

*Toxascaris leonina*

*Trichuris vulpis*

*Crenosoma vulpis* (Reduction of the level of infection).

*Angiostrongylus vasorum* (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under section “Dosage for each species, routes and method of administration”).

*Thelazia callipaeda* (see specific treatment schedule under section “Dosage for each species, routes and method of administration”).

The veterinary medicinal product can also be used in the prevention of heartworm disease (*Dirofilaria immitis*), if concomitant treatment against tapeworms is indicated.

## 5. Contraindications

Do not use “**tablets for small dogs and puppies**” in animals of less than 2 weeks of age and/or weighing less than 0.5 kg.

Do not use “**tablets for dogs**” in animals weighing less than 5 kg.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

See also section “Special warnings”.

## 6. Special warnings

### Special warnings:

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

It is recommended to treat all the animals in the same household concomitantly.

In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the dog should be taken into account, and it is recommended to seek professional advice.

When *D. caninum* infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection.

### Special precautions for safe use in the target species:

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

The tolerance of the veterinary medicinal product in young puppies from these breeds has not been investigated.

Clinical signs in Collies are similar to those seen in the general dog population when overdosed.

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes,

vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the veterinary medicinal product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using the veterinary medicinal product, a veterinary consultation is advised to exclude the presence of any concurrent infestation of *Dirofilaria immitis*. In the case of a positive diagnosis, adulticidal therapy is indicated before administering the veterinary medicinal product.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The veterinary medicinal product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of animals less than 4 weeks old with a combination veterinary medicinal product may therefore not be necessary.

As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental ingestion of a tablet by a child may be harmful. In order to prevent children from accessing the veterinary medicinal product, tablets should be administered and stored out of sight and reach of children.

Part tablets should be returned to the open blister pocket and inserted into the outer carton.

In the event of accidental ingestion of one or more tablets, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

#### Other precautions:

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology).

#### Pregnancy and lactation:

Can be used during pregnancy and lactation.

#### Fertility:

Can be used in breeding animals.

#### Interaction with other medicinal products and other forms of interaction:

No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the combination of milbemycin oxime and praziquantel at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the veterinary medicinal product and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Overdose:

No other signs than those observed at the recommended dose have been observed (see “Adverse events”).

**7. Adverse events**

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction; Systemic disorders (e.g. lethargy); Neurological disorders (e.g. muscle tremors and ataxia (incoordination)); Digestive tract disorders (e.g. emesis (vomiting), diarrhoea, anorexia (loss of appetite) and drooling).
--	--

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

**8. Dosage for each species, routes and method of administration**

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

Depending on the bodyweight of the dog, the practical dosing is as follows:

Body weight	Film-coated tablets for small dogs and puppies	Film-coated tablets for dogs
0.5 – 1 kg	1/2 tablet	
more than 1 – 5 kg	1 tablet	
more than 5 – 10 kg	2 tablets	
5 – 25 kg		1 tablet
more than 25 – 50 kg		2 tablets
more than 50 – 75 kg		3 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the veterinary medicinal product can replace the monosubstance veterinary medicinal product for the prevention of heartworm disease.

For treatment of *Angiostrongylus vasorum* infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against tapeworms is indicated, to treat once with the veterinary medicinal product and continue with the monovalent veterinary medicinal product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the veterinary medicinal product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against tapeworms is indicated.

For the treatment of *Thelazia callipaeda*, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against tapeworms is indicated, the veterinary medicinal product can replace the monosubstance veterinary medicinal product containing milbemycin oxime alone.

## **9. Advice on correct administration**

The veterinary medicinal product should be administered with or after some food. The veterinary medicinal product is palatable i.e. it is usually taken voluntarily by dogs (voluntary consumption on > 80% of occasions in animals studied). If the dog does not voluntarily accept the tablet, it can also be administered into the mouth.

## **10. Withdrawal periods**

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store in the original package in order to protect from moisture.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister after Exp. The expiry date refers to the last day of that month.

Shelf life for halved tablets for small dogs and puppies after first opening the immediate packaging: 6 months.

Halved tablets should be stored below 25°C in the original blister and be used for the next administration.

Keep the blister in the outer carton.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

This veterinary medicinal product should not enter water courses as milbemycin oxime may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription (BE, BG, CZ, DE, EE, ES, UK (NI), HR, HU, IE, IT, LV, PL, PT, RO, SK).

Veterinary medicinal product not subject to prescription (LT, NL).

Veterinary medicinal product subject to prescription except for some pack sizes (FR, SI).

## **14. Marketing authorisation numbers and pack sizes**

Vm 01656/3083

Vm 01656/3082

Cardboard box with 1 blister of 2 tablets.

Cardboard box with 1 blister of 4 tablets.

Cardboard box with 12 blisters, each blister contains 4 tablets (total 48 tablets).

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer responsible for batch release:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## **17. Other information**

Approved 07 January 2025

*Gavin Hall*